An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

Novo Nordisk should perform well thanks to new leadership and a strong underlying business. Exelixis' main oncology franchise ...

Doctors are also seeing success in treating people with certain liver diseases. Isaacs prescribes GLP-1s for people with a ...

Innovent announces phase 3 study of mazdutide in Chinese adults with overweight or obesity (GLORY-1) published in the NEJM: San Francisco, US Tuesday, May 27, 2025, 11:00 Hrs [IST ...

The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their ...

In early April, President Donald Trump gathered dozens of hard-hat-clad coal miners around him in the White House East Room.

The list of benefits for Novo Nordisk's semaglutide keeps getting longer. Now, it seems the GLP-1 agonist could help patients with heart failure, adding to earlier studies showing it can treat ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...